Tag Archive for: oncology

Ona Therapeutics Strengthens Leadership Team to Accelerate First-in-Class ADCs into Clinical Development Across Cancer Types

Dr. Aleix Prat, an internationally recognized leader in drug and biomarker development appointed Chair of the Advisory Board Dr. Jutta Amersdorffer appointed as Chief Medical Officer and Stéphane Durant des Aulnois appointed as Chief Financial Officer Accelerating development of first-in-class ADCs in multiple large solid tumor types designed against novel targets with a focus on […]

U.S. FDA Grants Orphan Drug Designation to Ariceum Therapeutics’ Proprietary Radiopharmaceutical Cancer Therapy

225Ac-satoreotide is a first-in-class Actinium-labelled somatostatin receptor 2 antagonist targeting extensive-stage Small Cell Lung Cancer or Merkel Cell Carcinoma Orphan Drug Designation follows outstanding preclinical data and FDA IND clearance Phase I/II human trials set to commence in Q1 2025 as a ‘theranostic’ targeted radionuclide treatment Berlin, Germany, 6 February 2025 – Ariceum Therapeutics (Ariceum), a […]

Hot topic: JPM shines bright amid the January gloom

2025 has already begun with drama in the U.S., as Los Angeles recovers from deadly wildfires and Donald Trump is sworn in for his second presidency. And so it was that the mood going into the annual JP Morgan Healthcare Conference was clouded by uncertainty. With its timing in January, JPM is often seen as […]

FDA Clears Ariceum Therapeutics’ ²²⁵Ac-Satoreotide Phase I/II Clinical Study in Patients with Small Cell Lung Cancer or Merkel Cell Carcinoma

225Ac-SSO110 (satoreotide) is a first in class Actinium-labelled SSTR2 receptor antagonist Phase I/II SANTANA-225 study on track to enrol patients in Q1 2025 Berlin, Germany, 14 January 2025 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced that the US Food and Drug […]

Ariceum Therapeutics and ITM Enter Supply Agreement for Therapeutic Medical Radioisotope Actinium-225

Berlin, Germany / Garching / Munich, January 13, 2025 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, and ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the execution of a supply agreement for non-carrier-added (n.c.a.) Actinium-225 (Ac-225) to support the development […]